McKesson Stock Falls 1.13% as Venture Arm Leads $20M Prudentia Series A
McKesson concluded the session at $814.63, down 1.13% from its prior close. Its venture arm led a $20 million Series A for Prudentia Sciences, bringing the AI due diligence firm's total funding to $27 million.
1. Stock Underperforms Broad Market
McKesson’s shares declined by 1.13% during the latest trading session, contrasting with a 0.8% advance in the S&P 500. The stock’s relative underperformance marks its third down day in five sessions, reflecting growing investor caution amid healthcare distribution sector volatility.
2. Venture Arm Drives Strategic Investment
McKesson Ventures led a $20 million Series A financing round for Prudentia Sciences, a Cambridge-based AI due diligence platform for life-sciences deals. This latest investment brings Prudentia’s total funding to $27 million and underscores McKesson’s commitment to digital innovation in pharma dealmaking.